Literature DB >> 1495006

3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.

M J Camarasa1, M J Pérez-Pérez, A San-Félix, J Balzarini, E De Clercq.   

Abstract

A series of 3'-spiro nucleosides have been synthesized and evaluated as anti-HIV-1 agents. Reaction of O-mesylcyanohydrins of furanos-3'-ulosyl nucleosides with base afforded [1-[2',5'-bis-O- (tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranosyl]]-3'-spiro-5"- [4"-amino-1",2"-oxathiole 2",2"-dioxide] derivatives of thymine, uracil and 4-N-acetylcytosine 11 and 12. Desilylation of 11 and 12 gave the full deprotected 3'-spiro xylo- and ribofuranosyl nucleosides 13 and 14 or the partially 5'-O-deprotected-3'-spiro beta-D-xylo- and -ribo-nucleosides 15 and 16, or 2'-O-deprotected-3'-spiro beta-D-ribo-nucleoside 17. 2'-Deoxygenation of 17 afforded 2'-deoxy-3'-spiro beta-D-erythro-pentofuranosyl derivative 18. These 3'-spiro derivatives were evaluated for their anti-HIV-1 activity. All 3'-spiro nucleosides having a xylo configuration did not show any anti-HIV-1 activity. 3'-Spiro ribo-nucleosides with none or only one silyl group at C-2' or C-5' or the 2'-deoxy derivative were also inactive at subtoxic concentrations. However, 3'-spiro ribo-nucleosides having two silyl groups at C-2' and C-5' were potent and selective inhibitors of HIV-1. None of the nucleoside analogues that showed anti-HIV-1 activity proved inhibitory to the replication of HIV-2 or SIV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495006     DOI: 10.1021/jm00093a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors:  H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; W G Tarpley; E De Clercq
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

4.  Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.

Authors:  Kalyan Das; Joseph D Bauman; Angela S Rim; Chhaya Dharia; Arthur D Clark; María-José Camarasa; Jan Balzarini; Eddy Arnold
Journal:  J Med Chem       Date:  2011-03-29       Impact factor: 7.446

5.  Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.

Authors:  J Balzarini; M J Camarasa; M J Pérez-Pérez; A San-Félix; S Velázquez; C F Perno; E De Clercq; J N Anderson; A Karlsson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 7.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.

Authors:  J Balzarini; A Karlsson; V V Sardana; E A Emini; M J Camarasa; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

9.  Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).

Authors:  J Balzarini; M J Pérez-Pérez; S Vélazquez; A San-Félix; M J Camarasa; E De Clercq; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.

Authors:  J Balzarini; A Karlsson; C Meichsner; A Paessens; G Riess; E De Clercq; J P Kleim
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.